Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

Melanoma, a skin cancer associated with high mortality rates, is highly radio-and
chemotherapy resistant but can also be very immunogenic. These circumstances have led to …

Checkpoint blockade enhances effector T cell function and has elicited long-term remission
in a subset of patients with a broad spectrum of cancers. TIGIT is a checkpoint receptor …

Immune-checkpoint blockade is able to achieve durable responses in a subset of patients;
however, we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4 …

Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …